These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11812081)

  • 1. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Plaxe SC; Blessing JA; Husseinzadeh N; Webster KD; Rader JS; Dunton CJ
    Gynecol Oncol; 2002 Feb; 84(2):241-4. PubMed ID: 11812081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Bookman MA; Creasman WT
    Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Olt G; Husseinzadah N; Lentz SS; DeGeest K; Valea FA
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):151-4. PubMed ID: 12172981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group.
    Moore DH; Blessing JA; Dunton C; Buller RE; Reid GC
    Gynecol Oncol; 1999 Dec; 75(3):473-5. PubMed ID: 10600310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.
    Zalupski MM; Philip PA; LoRusso P; Shields AF
    Cancer Chemother Pharmacol; 1997; 40(3):225-7. PubMed ID: 9219505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
    Fracasso PM; Blessing JA; Molpus KL; Adler LM; Sorosky JI; Rose PG
    Gynecol Oncol; 2006 Nov; 103(2):523-6. PubMed ID: 16712905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
    Miller DS; Blessing JA; Drake RD; Higgins R; McMeekin DS; Puneky LV; Krasner CN
    Gynecol Oncol; 2009 Dec; 115(3):443-6. PubMed ID: 19804902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.
    Plaxe SC; Blessing JA; Lucci JA; Hurteau JA
    Invest New Drugs; 2001; 19(1):77-80. PubMed ID: 11291835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer.
    Pelley R; Ganapathi R; Wood L; Rybicki L; McLain D; Budd GT; Peereboom D; Olencki T; Bukowski RM
    Cancer Chemother Pharmacol; 2000; 46(3):251-4. PubMed ID: 11021744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study.
    Grendys EC; Blessing JA; Burger R; Hoffman J
    Gynecol Oncol; 2005 Aug; 98(2):249-53. PubMed ID: 15978659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
    Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study.
    Fowler JM; Blessing JA; Burger RA; Malfetano JH
    Gynecol Oncol; 2002 May; 85(2):311-4. PubMed ID: 11972393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.
    Garcia AA; Blessing JA; Nolte S; Mannel RS;
    Gynecol Oncol; 2008 Oct; 111(1):22-6. PubMed ID: 18675446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
    Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
    Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.
    Wadler S; Levy DE; Lincoln ST; Soori GS; Schink JC; Goldberg G
    J Clin Oncol; 2003 Jun; 21(11):2110-4. PubMed ID: 12775736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
    Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
    Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer.
    Small EJ; Fippin LJ; Whisenant SP
    Cancer Invest; 1998; 16(7):456-61. PubMed ID: 9774952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
    Traina TA; Sabbatini P; Aghajanian C; Dupont J
    Gynecol Oncol; 2004 Oct; 95(1):235-41. PubMed ID: 15385138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.